Page last updated: 2024-11-05

thalidomide and Aphthae

thalidomide has been researched along with Aphthae in 108 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)."9.09Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999)
"An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection."9.08Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995)
"Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)."9.05Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984)
"Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae."7.69Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995)
"We report our experience in the treatment of major and minor aphthae with thalidomide."7.67Treatment of aphthae with thalidomide. ( Agüero, S; Blanco, GF; Grinspan, D, 1989)
"During maintenance medication at the fourth and eighth weekend, the two doses (50 and 25 mg/d) of thalidomide were equivalent in reducing the incidence of ulcers, ulcer number, and ulcer pain, respectively (all p > 0."5.51A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. ( Deng, Y; Du, G; Pan, L; Tang, G; Wang, Y; Wei, W; Yao, H, 2022)
"The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum."5.12Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007)
"A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)."5.09Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999)
"An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection."5.08Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995)
"Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)."5.05Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984)
"English-language articles were identified through a MEDLINE search (1966-February 2001); key terms included thalidomide, child, graft-versus-host disease, cancer, HIV, Crohn's disease, Behçet's disease, and lupus erythematosus."4.81Thalidomide use in pediatric patients. ( Bessmertny, O; Pham, T, 2002)
"Six patients could stop the treatment and further presented minor aphthae, 10 needed minimal daily doses of thalidomide and 7 did not respond to 100 mg daily."3.69Thalidomide and recurrent aphthous stomatitis: a follow-up study. ( Bedane, C; Bonnetblanc, JM; Royer, C, 1996)
"Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae."3.69Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995)
"Thalidomide is being tested as an anti-HIV drug, a weight loss treatment, an immune system regulator, a tuberculosis treatment supplement, and a treatment for microsporidiosis."3.69Treatment for weight loss, tuberculosis and AIDS? ( , 1995)
"Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years."3.67Development of polyneuropathy during thalidomide therapy. ( Asboe-Hansen, G; Brodthagen, H; Høyer, H; Wulff, CH, 1985)
"Thalidomide alone (200-300 mg daily) or associated with colchicine (2-3 mg daily) was given orally to 25 patients with aphthosis: 8 patients with recurrent oral aphthae; 4 patients with recurrent mucocutaneous aphthosis, without visceral involvement, and 13 patients with Behçet's disease (Touraine's aphthosis)."3.67[Treatment of aphthosis with thalidomide and with colchicine]. ( Faure, M; Genvo, MF; Thivolet, J, 1984)
"We report our experience in the treatment of major and minor aphthae with thalidomide."3.67Treatment of aphthae with thalidomide. ( Agüero, S; Blanco, GF; Grinspan, D, 1989)
"Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug."3.66[Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983)
"After 1 month, the increase in the recurrence interval was not shown to differ between the two groups (P = ."2.94The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial. ( Shi, J; Shi, X; Yang, J; Yang, M; Zeng, Q; Zhao, W; Zhao, X; Zhou, H, 2020)
"Colchicine was administered to a total of ten patients, with benefits observed in nine (90%), of whom four showed complete remission."2.74Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. ( Hirota, SK; Migliari, DA; Mimura, MA; Sanches, JA; Sugaya, NN, 2009)
"Thalidomide in lower intermittent doses is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons."2.70Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Hooton, TM; Jackson, JB; Jacobson, JM; Pulvirenti, JJ; Shikuma, C; Spritzler, J; Wohl, DA, 2001)
"Thalidomide has increasing clinical benefits, including the healing of aphthous ulcers in patients with HIV."2.70Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ( Aweeka, F; Bellibas, SE; Chernoff, M; Jacobson, J; Jayewardene, A; Lizak, P; Spritzler, J; Trapnell, C, 2001)
"Thalidomide was first developed and marketed in Germany in the 1950s as a sedative."2.68Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores). ( Manesis, DA, 1995)
"Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection."2.68Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Jackson, JB; Jacobson, JM; Ketter, N; MacPhail, LA; Spritzler, J; Vasquez, GJ; Wohl, DA; Wu, AW, 1997)
" We concluded that thalidomide in a dosage of 100 mg/d is an effective treatment of severe aphthous stomatitis but is not without some risk."2.67Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. ( Bonnetblanc, JM; Claudy, A; Dallac, S; Guillaume, JC; Hans, P; Janier, M; Klene, C; Marchand, C; Revuz, J; Souteyrand, P, 1990)
" Data on patient response to treatment and major/minor adverse events were obtained from their clinical and electrophysiologic records."2.66Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients. ( Harte, MC; Hodgson, TA; Saunsbury, TA, 2020)
"Thalidomide is second-line treatment for aphthous stomatitis and chronic graft-versus-host disease in children and has been prescribed for many other conditions including actinic prurigo and epidermolysis bullosa pruriginosa."2.52Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015)
"Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects."2.43Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005)
"Recurrent aphthous stomatitis is a common problem with 20% to 50% of the population having experienced simple aphthous lesions (ie, canker sores)."2.43Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. ( Jorizzo, JL; Letsinger, JA; McCarty, MA, 2005)
"Aphthous ulcers are among the most common oral lesions in the general population, with a frequency of up to 25% and three-month recurrence rates as high as 50%."2.41Treatment strategies for recurrent oral aphthous ulcers. ( Barrons, RW, 2001)
"Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation."2.41Thalidomide: an antineoplastic agent. ( Amato, RJ, 2002)
"Apremilast is a phosphodiesterase 4 inhibitor used in psoriasis and psoriatic arthritis Recently, this treatment has received marketing authorization for severe and refractory oral aphthosis in Behçet's disease."1.72[Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases]. ( Delaumenie, S; Fourmond, S; Gourin, MP; Gutierrez, B; Ly, KH, 2022)
"Thalidomide regulated gut dysbacteriosis in a species-specific manner and had different sustainable effects on various probiotics and pathogens."1.72A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide. ( Duan, N; Hu, Q; Huang, F; Huang, J; Jiang, H; Lin, L; Liu, Q; Qian, Y; Ruan, H; Song, Y; Wang, W; Wang, X; Xiong, K; Yan, F; Ye, P; Zhao, M; Zheng, L; Zhu, Y, 2022)
"Since then, the patient has had two recurrences, coinciding with the reduction of thalidomide dosages, which were controlled by increasing the dose of the immunomodulator."1.48A Dramatic Case of Odynophagia. ( Diniz-Freitas, M; Diz, P; García-Caballero, L; Limeres, J; Seoane, J; Sopeña, B, 2018)
"Thalidomide has reported efficacy in treating refractory idiopathic aphthous ulceration and aphthous ulceration in Behçet disease (BD)."1.38Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience. ( Cheng, S; Murphy, R, 2012)
"Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed."1.36[Recurrent aphthosis: safety of low dose thalidomide]. ( Dupond, JL; Gil, H; Hafsaoui, C; Limat, S; Magy-Bertrand, N; Meaux-Ruault, N; Perrin, S, 2010)
"Thalidomide was rapidly effective: 85% (78/92) entered complete remission (CR) within a median of 14 days."1.36Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. ( Barbarot, S; Bastuji-Garin, S; Chosidow, O; Hello, M; Revuz, J, 2010)
"Thalidomide is a drug associated with devastating side effects."1.30Thalidomide's long and winding road. ( Hanna, L, 1998)
"Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs."1.30[Thalidomide once more in the spotlight]. ( Cornel, MC; de Jong-van den Berg, LT; Rutgers, J, 1998)
"All patients had oral and genital aphthae, and 22 of 25 patients had cutaneous lesions consistent with Behçet's disease."1.29Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. ( Jorizzo, JL; Mangelsdorf, HC; White, WL, 1996)
"Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services."1.29Thalidomide and HIV: several possible uses. ( Smith, D, 1995)
"An increasing number of AIDS patients have been noted to suffer severe recurrent aphthous stomatitis (RAS), a condition often associated with high morbidity that remains unresponsive to conventional therapeutic interventions."1.28Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. ( Nicolau, DP; West, TE, 1990)

Research

Studies (108)

TimeframeStudies, this research(%)All Research%
pre-199016 (14.81)18.7374
1990's53 (49.07)18.2507
2000's19 (17.59)29.6817
2010's9 (8.33)24.3611
2020's11 (10.19)2.80

Authors

AuthorsStudies
Deng, Y1
Wei, W1
Wang, Y1
Pan, L1
Du, G1
Yao, H1
Tang, G1
Fourmond, S1
Gutierrez, B1
Gourin, MP1
Delaumenie, S1
Ly, KH1
Banday, AZ1
Joshi, V1
Arora, K1
Sadanand, R1
Basu, S1
Pilania, RK1
Jindal, AK1
Vignesh, P1
Gupta, A1
Sharma, S1
Dhaliwal, M1
Rawat, A1
Singh, S1
Suri, D1
Wang, X1
Xiong, K1
Huang, F1
Huang, J1
Liu, Q1
Duan, N1
Ruan, H1
Jiang, H1
Zhu, Y1
Lin, L1
Song, Y1
Zhao, M1
Zheng, L1
Ye, P1
Qian, Y1
Hu, Q1
Yan, F1
Wang, W1
Mahé, E1
Zeng, Q1
Shi, X1
Yang, J1
Yang, M1
Zhao, W1
Zhao, X1
Shi, J1
Zhou, H1
Galán Sánchez, JL1
Eguren Michelena, C1
de la Cueva Dobao, P1
Kolios, AGA1
Yawalkar, N1
Feusi, A1
Kündig, T1
Boyman, O1
Nilsson, J1
Harte, MC1
Saunsbury, TA1
Hodgson, TA1
Arasu, A1
Lee, S1
Chian Yeoh, A1
Ross, G1
Soriano, A1
Soriano, M1
Espinosa, G1
Manna, R1
Emmi, G1
Cantarini, L1
Hernández-Rodríguez, J1
Sopeña, B1
Limeres, J1
García-Caballero, L1
Diniz-Freitas, M1
Seoane, J1
Diz, P1
Giácaman von der Weth, MM1
Tapial, JM1
Guillén, BF1
Ferrer, DS1
Sánchez-Carazo, JL1
Ninet, VZ1
Saini, A1
Ferguson, C1
Salkey, K1
Kalampokis, I1
Rabinovich, CE1
Taylor, J1
Glenny, AM1
Walsh, T1
Brocklehurst, P1
Riley, P1
Gorodkin, R1
Pemberton, MN1
Yang, CS1
Kim, C1
Antaya, RJ1
Mimura, MA1
Hirota, SK1
Sugaya, NN1
Sanches, JA1
Migliari, DA1
Gil, H1
Perrin, S1
Dupond, JL1
Meaux-Ruault, N1
Hafsaoui, C1
Limat, S1
Magy-Bertrand, N1
Hello, M1
Barbarot, S1
Bastuji-Garin, S1
Revuz, J3
Chosidow, O1
Cheng, S1
Murphy, R1
Shetty, K1
Ben Slama, L1
Sarmadi, M2
Ship, JA2
Letsinger, JA1
McCarty, MA1
Jorizzo, JL2
Wu, JJ1
Huang, DB1
Pang, KR1
Hsu, S1
Tyring, SK1
Marque, M1
Guillot, B1
Bessis, D1
Sharma, NL1
Sharma, VC1
Mahajan, VK1
Shanker, V1
Ranjan, N1
Gupta, M1
Grosshans, E1
Illy, G1
Jenkins, JS1
Powell, RJ3
Allen, BR2
Littlewood, SM1
Maurice, PD2
Smith, NJ2
Bowers, PW1
Genvo, MF1
Faure, M1
Thivolet, J1
Torras, H2
Lecha, M2
Mascaró/, JM1
Hunziker, T1
Krebs, A1
Thompson, C1
Gershon, D1
Manders, SM1
Kostman, JR1
Mendez, L1
Russin, VL1
Laccourreye, O1
Fadlallah, JP1
Pages, JC1
Durand, H1
Brasnu, D1
Lowenstein, W1
Paterson, DL1
Georghiou, PR1
Allworth, AM1
Kemp, RJ1
Henriquet, F1
Roy, MT2
Repetto, T2
Fusco, F1
Oldfield, EC1
Bodokh, I1
Lacour, JP1
Rainero, C1
Castanet, J1
Michiels, JF1
Ortonne, JP1
Menni, S1
Imondi, D1
Brancaleone, W1
Croci, S1
Ghigliotti, G1
Farris, A1
De Marchi, R1
Mangelsdorf, HC1
White, WL1
Solèr, RA1
Migliorati, C1
van Waes, H1
Nadal, D1
Weidle, PJ1
Harry, TC1
Bonnetblanc, JM2
Royer, C1
Bedane, C1
Ball, SC1
Sepkowitz, KA1
Jacobs, JL1
Jacobson, JM3
Greenspan, JS2
Spritzler, J4
Ketter, N1
Fahey, JL3
Jackson, JB3
Fox, L3
Chernoff, M4
Wu, AW2
MacPhail, LA2
Vasquez, GJ1
Wohl, DA3
Bassetti, S1
Courvoisier, S1
Itin, P1
Birnkrant, D1
Sharp, M1
Getty, J1
Klausner, JD1
MacPhail, L1
Lacosta Nicolás, JL1
Martínez Iñiguez, JC1
de Jong-van den Berg, LT1
Rutgers, J1
Cornel, MC1
Hooton, TM2
Sha, BE1
Shikuma, CM1
Simpson, DM1
Trapnell, CB1
Basgoz, N1
Gompel, A1
Frances, C1
Piette, JC1
Blanc, AS1
Cordoliani, F1
Piette, AM1
Calabrese, L1
Fleischer, AB1
Pulvirenti, JJ1
Shikuma, C1
Barrons, RW1
Chavez, EM1
Doerr, PA1
Henson, BS1
Esteve, E1
Legac, E1
Manesis, DA1
Smith, D1
Lowell, B1
Gilden, D1
Baker, R1
James, JS1
Randall, P1
Cooper, S1
Hanna, L1
Moraes, M1
Russo, G1
Aweeka, F1
Trapnell, C1
Jayewardene, A1
Bellibas, SE1
Lizak, P1
Jacobson, J1
Taiwo, BO1
Amato, RJ1
Bessmertny, O1
Pham, T1
Mascaro, JM1
Higgins, SP1
Bradbeer, CS1
Strazzi, S1
Lebbe, C1
Geoffray, C1
Ablon, G1
Morel, P1
Verola, O1
Molina, JM1
Williams, I1
Weller, IV1
Malni, A1
Anderson, J1
Waters, MF1
Boisnic, S1
Tovaru, S1
Santis, HR1
Allegue, F1
Sarriá Cepeda, C1
García Rodríguez, M1
Tercedor, J1
Ortego, N1
Ródenas, JM1
Hernández, J1
Youle, M2
Hawkins, D2
Gazzard, B2
Samson, J2
Kuffer, R2
Radeff, B2
Guillaume, JC1
Janier, M1
Hans, P1
Marchand, C1
Souteyrand, P1
Claudy, A1
Dallac, S1
Klene, C1
Nicolau, DP1
West, TE1
Clarbour, J1
Farthing, C1
Connolly, M1
Staughton, R1
Grinspan, D2
Blanco, GF1
Agüero, S1
Jenkins, S1
Littlewood, S1
Wulff, CH1
Høyer, H1
Asboe-Hansen, G1
Brodthagen, H2
Eisenbud, L1
Horowitz, I1
Kay, B1
Pinquier, L1
Kürkçüoğlu, N1
Atakan, N1
Eksioğlu, M1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease: A Randomized Clinical Trial[NCT06084624]Phase 1/Phase 240 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients[NCT00001524]Phase 2110 participants Interventional1996-06-30Completed
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790]Phase 2164 participants InterventionalCompleted
A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding[NCT02754960]Phase 20 participants (Actual)Interventional2010-03-31Withdrawn
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496]Phase 255 participants (Actual)Interventional2004-11-30Completed
The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949]Phase 20 participants (Actual)Interventional2015-12-31Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cessation of Bleeding

The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months

Interventionparticipants (Number)
Thalidomide Group13
Iron-controlled Group0

Change From Baseline in Bleeding Duration at 12 Months

The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months

Interventiondays (Mean)
Thalidomide Group5.2
Iron-controlled Group0.8

Change From Baseline in Bleeding Episodes at 12 Months

The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months

Interventionbleeding episodes (Mean)
Thalidomide Group-9.36
Iron-controlled Group1.41

Change From Baseline in Hemoglobin (Hb) Level at 12 Months

The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months

Interventiong/L (Mean)
Thalidomide Group3.06
Iron-controlled Group-0.01

Change From Baseline in Total Transfused Red Cell Requirements at 12 Months

Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months

Interventionmilliliter (Mean)
Thalidomide Group-1585.71
Iron-controlled Group-28.57

Participants Dependent on Blood Transfusions

Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months

Interventionparticipants (Number)
Thalidomide Group3
Iron-controlled Group13

Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months

The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months

Interventionparticipants (Number)
Thalidomide Group20
Iron-controlled Group1

Reviews

20 reviews available for thalidomide and Aphthae

ArticleYear
Challenges in the diagnosis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome in developing countries-A decade of experience from North India.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Antipyretics; Antiviral Agents; Child; Colchicine; Developing Countries; Fever; Humans; Lymphadeniti

2022
Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2020, Volume: 130, Issue:4

    Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Mouth Diseases; Retrospective Studies; Stom

2020
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve

2020
Interventions for the management of oral ulcers in Behçet's disease.
    The Cochrane database of systematic reviews, 2014, Sep-25, Issue:9

    Topics: Acyclovir; Adrenal Cortex Hormones; Alanine; Behcet Syndrome; Colchicine; Cyclosporine; Etanercept;

2014
Review of thalidomide use in the pediatric population.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:4

    Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au

2015
Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide.
    Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:3 Pt 1

    Topics: Adult; Algorithms; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Male; Recurrence; Stoma

2005
Thalidomide: dermatological indications, mechanisms of action and side-effects.
    The British journal of dermatology, 2005, Volume: 153, Issue:2

    Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh

2005
Thalidomide therapy for inflammatory dermatoses.
    International journal of dermatology, 1984, Volume: 23, Issue:9

    Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity

1984
Sutton's disease (periadenitis mucosa necrotica recurrens).
    The Annals of otology, rhinology, and laryngology, 1995, Volume: 104, Issue:4 Pt 1

    Topics: Adult; Colchicine; Diagnosis, Differential; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidom

1995
Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Feb-15, Volume: 53, Issue:4

    Topics: Clinical Trials as Topic; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Aphthous; Th

1996
Topical and systemic therapy for recurrent aphthous stomatitis.
    Seminars in cutaneous medicine and surgery, 1997, Volume: 16, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Analgesics; Anti-Inflammat

1997
[Treatment of recurrent aphthous stomatitis. A bibliographic review].
    Revista clinica espanola, 1998, Volume: 198, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Calcium Phosphates; Dinoprostone; Female; Glycopeptides; Humans; Imm

1998
Thalidomide: current and potential clinical applications.
    The American journal of medicine, 2000, Apr-15, Volume: 108, Issue:6

    Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent

2000
Treatment strategies for recurrent oral aphthous ulcers.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Jan-01, Volume: 58, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Aminopyridines; Anti-Infla

2001
Recurrent aphthous stomatitis.
    Quintessence international (Berlin, Germany : 1985), 2000, Volume: 31, Issue:2

    Topics: Administration, Topical; Anti-Inflammatory Agents; Glucocorticoids; Humans; Immunosuppressive Agents

2000
Thalidomide and its dermatologic uses.
    The American journal of the medical sciences, 2001, Volume: 321, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D

2001
Thalidomide: an antineoplastic agent.
    Current oncology reports, 2002, Volume: 4, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; HIV Infections; H

2002
Thalidomide use in pediatric patients.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:3

    Topics: Adolescent; Child; Chronic Disease; Female; Graft vs Host Disease; Humans; Hypnotics and Sedatives;

2002
[Evaluation and treatment of aphthous ulcerations of the mouth].
    Annales de dermatologie et de venereologie, 1991, Volume: 118, Issue:1

    Topics: Anti-Infective Agents, Local; Ascorbic Acid; Behcet Syndrome; Colchicine; Diagnosis, Differential; H

1991
Aphthous stomatitis and its management.
    Current opinion in dentistry, 1991, Volume: 1, Issue:6

    Topics: Adrenal Cortex Hormones; Humans; Stomatitis, Aphthous; Tetracycline; Thalidomide

1991

Trials

17 trials available for thalidomide and Aphthae

ArticleYear
A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2022, Volume: 51, Issue:1

    Topics: Double-Blind Method; Humans; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide

2022
The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2020, Volume: 49, Issue:4

    Topics: Double-Blind Method; Humans; Quality of Life; Recurrence; Stomatitis, Aphthous; Thalidomide

2020
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial.
    Clinics (Sao Paulo, Brazil), 2009, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Aged; Child; Colchicine; Dapsone; Drug Administration Schedule; Female; Follow-Up

2009
Thalidomide: an experience in therapeutic outcome and adverse reactions.
    The Journal of dermatological treatment, 2007, Volume: 18, Issue:6

    Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen

2007
Thalidomide in severe orogenital ulceration.
    Lancet (London, England), 1984, Dec-22, Volume: 2, Issue:8417-8418

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Genital Diseases, Fe

1984
Thalidomide effective for AIDS-related oral ulcers.
    Lancet (London, England), 1995, Nov-11, Volume: 346, Issue:8985

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Esophageal Diseases; Humans; Placebos; Sto

1995
Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 20, Issue:2

    Topics: Adult; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Stomatit

1995
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    The New England journal of medicine, 1997, May-22, Volume: 336, Issue:21

    Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality

1997
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
    The Journal of infectious diseases, 1999, Volume: 180, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Double-Blind Method; Esophageal Diseases; E

1999
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
    The Journal of infectious diseases, 2001, Jan-15, Volume: 183, Issue:2

    Topics: Anti-HIV Agents; Double-Blind Method; HIV Infections; Humans; Immunosuppressive Agents; Recurrence;

2001
Thalidomide effective in treating AIDS-related mouth ulcers.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:1

    Topics: Adult; AIDS-Related Opportunistic Infections; Esophageal Diseases; Female; Humans; Immunosuppressive

1996
Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores).
    STEP perspective, 1995,Spring, Volume: 7, Issue:1

    Topics: CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; Humans; Placebos; Randomized Controlled T

1995
Thalidomide and aphthous ulcers.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Humans; Placebos; Stomatitis, Aphthous; Thalidomide

1995
Thalidomide for mouth ulcers and wasting.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995

    Topics: Cachexia; Double-Blind Method; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide

1995
Thalidomide effective treatment for AIDS-related mouth ulcers.
    NIAID AIDS agenda, 1995

    Topics: Esophagus; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide; Ulcer

1995
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group.
    Journal of clinical pharmacology, 2001, Volume: 41, Issue:10

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; Humans; Male; Middle Aged; Odds Ra

2001
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.
    Archives of dermatology, 1990, Volume: 126, Issue:7

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Randomized Controlle

1990

Other Studies

71 other studies available for thalidomide and Aphthae

ArticleYear
[Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
    La Revue de medecine interne, 2022, Volume: 43, Issue:5

    Topics: Behcet Syndrome; Humans; Quality of Life; Stomatitis, Aphthous; Thalidomide

2022
A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Dysbiosis; Gastrointestinal Microbiome; Humans; Metagenome; Stomatitis, Aphthous; Thalidomide

2022
Everolimus-induced aphthous stomatitis controlled by apremilast in a heart-transplant patient.
    Annales de dermatologie et de venereologie, 2023, Volume: 150, Issue:2

    Topics: Antineoplastic Agents; Everolimus; Humans; Stomatitis; Stomatitis, Aphthous; Thalidomide

2023
Apremilast for the treatment of oral aphthae in Behçet disease.
    Medicina clinica, 2020, 12-11, Volume: 155, Issue:11

    Topics: Administration, Oral; Behcet Syndrome; Humans; Oral Ulcer; Stomatitis, Aphthous; Thalidomide

2020
Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis.
    The New England journal of medicine, 2019, 11-14, Volume: 381, Issue:20

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance; Female; Humans; Male; Middle

2019
Drug survival of thalidomide for dermatological conditions: A single-centre review.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:1

    Topics: Dermatologic Agents; Humans; Prurigo; Skin Diseases; Stomatitis, Aphthous; Thalidomide

2021
A Dramatic Case of Odynophagia.
    Dysphagia, 2018, Volume: 33, Issue:1

    Topics: Aged; Humans; Immunosuppressive Agents; Male; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide

2018
Complex Aphthae Treated With Apremilast.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Oral Ulcer; Psoriasis; Stomati

2020
Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome
    Journal of drugs in dermatology : JDD, 2018, 12-01, Volume: 17, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Behcet Syndrome; Diagnosis, Differential; Drug

2018
Successful management of refractory pediatric-onset complex aphthosis with lenalidomide.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Recurrence; St

2014
[Recurrent aphthosis: safety of low dose thalidomide].
    La Revue de medecine interne, 2010, Volume: 31, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Male; Mid

2010
Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis.
    Medicine, 2010, Volume: 89, Issue:3

    Topics: Adolescent; Adult; Aged; Cohort Studies; Drug Tolerance; Drug-Related Side Effects and Adverse React

2010
Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience.
    Clinical and experimental dermatology, 2012, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Stomatitis, Aphthous

2012
Thalidomide for recurrent aphthous ulcerations.
    HIV clinician, 2003,Summer, Volume: 15, Issue:3

    Topics: AIDS-Related Opportunistic Infections; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide

2003
[Aphthae and aphthosis].
    Revue de stomatologie et de chirurgie maxillo-faciale, 2003, Volume: 104, Issue:5

    Topics: Anti-Bacterial Agents; Colchicine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Oral U

2003
Refractory major aphthous stomatitis managed with systemic immunosuppressants: a case report.
    Quintessence international (Berlin, Germany : 1985), 2004, Volume: 35, Issue:1

    Topics: Adult; Clinical Protocols; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Patient Educat

2004
Thalidomide for treatment of PFAPA syndrome.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:3

    Topics: Adult; Fever; Humans; Immunosuppressive Agents; Lymphadenitis; Male; Periodicity; Pharyngitis; Recur

2007
Effect of thalidomide on orogenital ulceration.
    British medical journal (Clinical research ed.), 1983, Sep-17, Volume: 287, Issue:6395

    Topics: Adult; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Recurrence; Stomatiti

1983
[Treatment of aphthosis with thalidomide and with colchicine].
    Dermatologica, 1984, Volume: 168, Issue:4

    Topics: Adult; Behcet Syndrome; Colchicine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Sk

1984
[Thalidomide in the treatment of aphthosis and Behçet's disease. 4 years' experience].
    Medicina cutanea ibero-latino-americana, 1982, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Aged; Behcet Syndrome; Drug Evaluation; Female; Humans; Male; Middle Aged; Necros

1982
[Thalidomide in dermatology].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1983, Volume: 34, Issue:2

    Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N

1983
Finding new uses for thalidomide.
    Nature medicine, 1995, Volume: 1, Issue:12

    Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Humans; Stomatitis, Aphthous; Thalidomide

1995
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor.
    Journal of the American Academy of Dermatology, 1995, Volume: 33, Issue:2 Pt 2

    Topics: Adult; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Stomatitis, Aphthous; Thalidom

1995
Thalidomide in oral aphthous ulceration in patients with HIV infection.
    Palliative medicine, 1994, Volume: 8, Issue:3

    Topics: Adult; Female; HIV Infections; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalidomide

1994
Thalidomide for severe aphthous ulceration in patients with human immunodeficiency virus (HIV) infection.
    The American journal of gastroenterology, 1994, Volume: 89, Issue:12

    Topics: Digestive System Diseases; HIV Infections; Humans; Severity of Illness Index; Stomatitis, Aphthous;

1994
[Efficacy of thalidomide against esophageal ulceration in HIV infection].
    Presse medicale (Paris, France : 1983), 1993, Sep-11, Volume: 22, Issue:26

    Topics: Adult; Esophageal and Gastric Varices; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomi

1993
Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide.
    Pediatric dermatology, 1993, Volume: 10, Issue:3

    Topics: Child; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide

1993
Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus.
    Journal of the American Academy of Dermatology, 1993, Volume: 28, Issue:2 Pt 1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Female; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalid

1993
New uses of thalidomide.
    The Medical letter on drugs and therapeutics, 1996, Feb-16, Volume: 38, Issue:968

    Topics: Erythema Nodosum; Humans; Stomatitis, Aphthous; Thalidomide

1996
Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement.
    Journal of the American Academy of Dermatology, 1996, Volume: 34, Issue:5 Pt 1

    Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Behcet Syndrome; Colchic

1996
Thalidomide treatment of mucosal ulcerations in HIV infection.
    Archives of disease in childhood, 1996, Volume: 74, Issue:1

    Topics: Adolescent; Female; Fissure in Ano; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Ap

1996
Thalidomide treatment of mucosal ulcerations in HIV infection.
    Archives of disease in childhood, 1996, Volume: 75, Issue:1

    Topics: HIV Infections; Humans; Leprostatic Agents; Stomatitis, Aphthous; Thalidomide

1996
Thalidomide and recurrent aphthous stomatitis: a follow-up study.
    Dermatology (Basel, Switzerland), 1996, Volume: 193, Issue:4

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Humans; Immunosu

1996
Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:1

    Topics: Adult; Female; HIV Seropositivity; Humans; Stomatitis, Aphthous; Thalidomide

1997
Thalidomide heals HIV-related oral ulcers, but caution is required.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Jul-01, Volume: 54, Issue:13

    Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide

1997
[Oral ulcers in HIV infection].
    Praxis, 1997, May-21, Volume: 86, Issue:21

    Topics: Adult; AIDS-Related Opportunistic Infections; Diagnosis, Differential; Humans; Immunosuppressive Age

1997
Thalidomide for aphthous ulcers in HIV infection.
    The New England journal of medicine, 1997, Oct-09, Volume: 337, Issue:15

    Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide; Viral Load

1997
Thalidomide use is associated with weight gain in HIV-1-positive clients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, Aug-15, Volume: 15, Issue:5

    Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male;

1997
Thalidomide pros and cons.
    The American journal of nursing, 1998, Volume: 98, Issue:4

    Topics: Double-Blind Method; Female; HIV Infections; HIV Wasting Syndrome; Humans; Immunosuppressive Agents;

1998
Thalidomide.
    The Medical letter on drugs and therapeutics, 1998, Oct-23, Volume: 40, Issue:1038

    Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Inf

1998
[Thalidomide once more in the spotlight].
    Nederlands tijdschrift voor geneeskunde, 1998, Nov-14, Volume: 142, Issue:46

    Topics: Adult; Bone Marrow Transplantation; Contraindications; Drug and Narcotic Control; Drug Approval; Fem

1998
Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al.
    Arthritis and rheumatism, 1999, Volume: 42, Issue:10

    Topics: Adult; Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vu

1999
Thalidomide: new preparation. For well-defined indications.
    Prescrire international, 1998, Volume: 7, Issue:37

    Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans;

1998
[Discoid lupus, recurrent aphthosis. New indications for thalidomide?].
    MMW Fortschritte der Medizin, 2001, Feb-22, Volume: 143, Issue:8

    Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Recurrence; Stomatitis, Aphthous; Th

2001
[Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide].
    Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:2

    Topics: Adult; Anticoagulants; Humans; Immunosuppressive Agents; International Normalized Ratio; Male; Pulmo

2001
Thalidomide and HIV: several possible uses.
    AIDS treatment news, 1995, Apr-21, Issue:no 221

    Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N

1995
Growing interest in thalidomide.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Cells, Cultured; Clinical Trials as Topic; Female; Humans

1995
Treatment for weight loss, tuberculosis and AIDS?
    Treatment review, 1995, Issue:no 20

    Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Stomatitis, Aphthous

1995
Thalidomide for wasting syndrome: progress toward compromise.
    AIDS treatment news, 1995, Nov-03, Issue:no 234

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response R

1995
Thalidomide, gentrified.
    Notes from the underground (New York, N.Y.), 1996, Issue:no 31

    Topics: Acquired Immunodeficiency Syndrome; Cachexia; Drug Costs; Female; Humans; Male; Stomatitis, Aphthous

1996
Thalidomide's long and winding road.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access

1998
Use of thalidomide in HIV infection.
    The AIDS reader, 2001, Volume: 11, Issue:10

    Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; HIV Infections; Humans; Recurrence;

2001
Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis.
    Archives of dermatology, 1979, Volume: 115, Issue:5

    Topics: Adult; Behcet Syndrome; Humans; Male; Recurrence; Skin Ulcer; Stomatitis, Aphthous; Thalidomide

1979
Thalidomide: a restricted role.
    Lancet (London, England), 1992, May-30, Volume: 339, Issue:8805

    Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide

1992
Aphthous ulcers in HIV-infected patients: treatment with thalidomide.
    Genitourinary medicine, 1992, Volume: 68, Issue:6

    Topics: Adult; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomide

1992
Thalidomide hypersensitivity in AIDS.
    Lancet (London, England), 1991, Feb-16, Volume: 337, Issue:8738

    Topics: Acquired Immunodeficiency Syndrome; Drug Hypersensitivity; Humans; Male; Stomatitis, Aphthous; Thali

1991
[Aphthosis major treated with thalidomide in a patient with AIDS].
    Enfermedades infecciosas y microbiologia clinica, 1991, Volume: 9, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Immunosuppressive Agents; Male; Stomatitis, Aphth

1991
[Treatment of recurrent aphthae with thalidomide in patients with acquired immunodeficiency syndrome].
    Medicina clinica, 1991, Jun-08, Volume: 97, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Stomatitis, Aphthous; Thalidomide; Time Fac

1991
Thalidomide in hyperalgic pharyngeal ulceration of AIDS.
    Lancet (London, England), 1990, Jun-30, Volume: 335, Issue:8705

    Topics: Acquired Immunodeficiency Syndrome; Humans; Hyperalgesia; Hyperesthesia; Pharyngeal Diseases; Stomat

1990
[Thalidomide, the treatment of choice in aphthae in HIV infection].
    Presse medicale (Paris, France : 1983), 1990, Apr-14, Volume: 19, Issue:15

    Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide

1990
Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.
    Journal of the American Academy of Dermatology, 1990, Volume: 23, Issue:3 Pt 1

    Topics: Administration, Topical; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Mouth Mucosa; Rec

1990
Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS.
    DICP : the annals of pharmacotherapy, 1990, Volume: 24, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Recurrence; Stomatitis, Aphthous; T

1990
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.
    BMJ (Clinical research ed.), 1989, Feb-18, Volume: 298, Issue:6671

    Topics: Adult; Female; HIV Seropositivity; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidomide

1989
Treatment of aphthae with thalidomide.
    Journal of the American Academy of Dermatology, 1989, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drug Evaluation; Female; Humans

1989
Thalidomide, orogenital ulcers, and risk of teratogenicity.
    Lancet (London, England), 1985, Mar-02, Volume: 1, Issue:8427

    Topics: Abnormalities, Drug-Induced; Female; Genital Diseases, Female; Humans; Pregnancy; Risk; Stomatitis,

1985
Development of polyneuropathy during thalidomide therapy.
    The British journal of dermatology, 1985, Volume: 112, Issue:4

    Topics: Action Potentials; Adult; Aged; Female; Humans; Leg; Male; Middle Aged; Neural Conduction; Neurons,

1985
Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide.
    Oral surgery, oral medicine, and oral pathology, 1987, Volume: 64, Issue:3

    Topics: Behcet Syndrome; Humans; Male; Middle Aged; Recurrence; Stomatitis, Aphthous; Thalidomide

1987
[Treatment of recurrent buccal aphthosis].
    Annales de dermatologie et de venereologie, 1987, Volume: 114, Issue:5

    Topics: Colchicine; Humans; Levamisole; Recurrence; Stomatitis, Aphthous; Thalidomide

1987
Significant response of oral aphthosis to thalidomide treatment.
    Journal of the American Academy of Dermatology, 1985, Volume: 12, Issue:1 Pt 1

    Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Middle Aged; Stomatitis, Aphthous; Thalidomide

1985
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae.
    The British journal of dermatology, 1985, Volume: 112, Issue:5

    Topics: Humans; Recurrence; Stomatitis, Aphthous; Thalidomide

1985
Significant response of oral aphthosis to thalidomide treatment.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:3

    Topics: Humans; Stomatitis, Aphthous; Thalidomide

1985